Background: Independent verification of the dose delivered by complex radiother-
| INTRODUCTION
It is recommended that all radiotherapy centers in the United Kingdom have a protocol for accurately measuring the dose delivered to a patient during a course of radiotherapy and comparing this to the planned dose. [1] [2] [3] [4] This approach, commonly known as transit or IVD, has its origins in the 1980s and 1990s when radiographic and radiochromic films were used for this purpose. More recently thermoluminescent detectors (TLDs), semiconductor diodes, metal-oxide field effect transistors (MOSFETs), and optically stimulated luminescence dosimeters (OSLDs) have been used for point dose measurements. [5] [6] [7] However, there are inherent difficulties with each of these approaches, which have been comprehensively reviewed in several key publications. [8] [9] [10] [11] Many of the limitations of these dosimeters can be overcome by the use of EPIDs, which although developed primarily for imaging, are now widely used as dosimeters and consequently for treatment verification. [11] [12] [13] [14] [15] EPIDs, like the aforementioned dosimeters, can be used for either pretreatment verification without the patient present or, as discussed here, for IVD where the patient is present. The main challenge in using EPIDs as dosimeters is in the mapping between the EPID images into dose, with two techniques commonly used for this purpose. In the first a portal dose image is predicted from the treatment plan and the computerized tomography (CT) images used for planning, which is compared to the measured portal dose image. In the second, the measured portal dose image is combined with a back-projection algorithm to calculate the dose in any given CT voxel and hence received by a patient.
The most widespread use of EPIDs as dosimeters has been in pretreatment verification. [16] [17] [18] However, there are limitations associated with pretreatment verification for detecting certain errors such as those associated with patient anatomy. 19 Furthermore patientspecific pretreatment verification requires additional quality assur- The DC software has two main technical elements. The first is that there is a mapping between the EPID fluence and the monitor units (MU) that would produce the same exposure at the center of a 10 × 10 cm 2 field at the appropriate reference conditions. The output of this mapping is termed the relative monitor unit (RMU). The second is that the scatter within the EPID housing must be taken into account to allow this new unit of RMU to independently calculate the dose received by a patient. This is done by deconvolution of the EPID fluence with the point spread function (PSF) of the EPID, which produces the RMU in terms of in-air fluence.
In practice the PSF has to take into account the dependence of the EPID on the input beam energy and the additional low-energy scatter radiation reaching the EPID from the presence of a patient in
the beam. In DC this is done at commissioning by calculating the PSF for a beam incident on and exiting water at regular intervals from 5 cm up to a maximum of 60 cm between the EPID and the radiation source.
2.A.1 | Relative monitor units
To obtain the absorbed dose (cGy) from the EPID, integrated EPID images are first mapped to RMU, which was defined by Renner as the number of MU that produces the same EPID pixel gray levels as a well-controlled calibration condition. 24 This is usually the 10 × 10 cm 2 reference field that is used to define the output of a linear accelerator, typically as, "1.0 cGy/MU at 10 × 10 cm 2 field size at 100 cm from the surface of water at 1.5 cm depth for 6 MV x rays a ." In the case of open square fields this may be thought of as the collimator scatter factor (S C ) multiplied by the output (MU).
The first step in converting an integrated EPID image into RMU is to establish the relationship between the EPID signal at the central axis of a 10 × 10 cm 2 field and the corresponding MU required to obtain this signal. To account for points not on the central axis, or off-axis points, the in-air off-axis ratio (OAR) along the diagonals of a 40 × 40 cm 2 field are measured to obtain the average OAR.
Multiplying EPID pixels at a distance r cm from the central axis by this value restores the horns on a crossbeam profile, which arise as a result of using a flattening filter.
2.A.2 | In vivo dose evaluation
From this knowledge of the fluence at each pixel of the EPID, which is in RMU, and the beam geometry and patient CT it is possible to ray trace from the x-ray source through the equivalent thickness of water that would produce this fluence. The same principle is applied when the planning CT is used in place of water and ray tracing is used to establish the dose at a point in the CT and hence the patient. The fluence map collected by the EPID image is the source of input for the DC dose calculation engine. This fluence map is used to parameterize the independent pencil beam dose calculation (PBC) algorithm that is used by DC. The dose calculated by DC is next compared to the dose matrix calculated by the treatment planning system. Quantitative evaluation of the difference between the planned and measured dose distribution is carried out in DC using either whole volume or partial volume gamma analysis or by a point dose comparison. 30 The DC software platform has been used for IVD at the Edin- Þ using a downhill search optimization algorithm. 25 Convergence was obtained when the variance, defined by,
2.B | Dosimetry Check -clinical implementation
over m data points was within 2%. Table 1 shows the range of treatment sites, the total number of treatment plans verified and the alerts produced by the system. The mean and standard deviation ðl AE rÞ of VMAT cases was found to be What is interesting to note from the 3DCRT IVD results is the diversity in the percentage dose difference between DC and Eclipse in breast, lung, H&N, and prostate cancer patients. In breast there was a -2.95% mean difference between the dose calculated in Eclipse and the IVD dose at a defined reference point. In lung there was a 2.6% difference, in H&N a 1.66% difference and in prostate a −3.62% difference. While these results indicate that the IVD values obtained by measurement are, in general, within the departmental tolerance of ±10% for all treatment sites they highlight systematic differences in the point dose measurements used for verification of breast, lung, H&N, and prostate cancer treatments. This may be as a result of the different approaches used for planning these treatments and selection of the reference point. It may also be due to the fundamental technical differences between DC and Eclipse, which requires further investigation.
3.B | Radiotherapy courses and patients
Ninety-six percent of the 3795 patients included passed the departmental alert criteria set for an acceptable difference (±10%) between the planned and delivered (in vivo) dose. Of those cases that exceeded the ±10% tolerance the majority were found to be in patients with breast, prostate, and H&N cancer. The reason for the alerts in the breast group was due to several compounding factors.
These were (a) changes in the volume of breast irradiated at each fraction due to the inherent difficulties in positioning of the breast; (b) chest wall irradiation, particularly the impact of rib structures in the field and the resulting uncertainties in the dose; (c) in nodal breast irradiation where the EPID imager position has to be shifted, no off-axis correction is currently applied in the calculation; (d) currently breast patients are treated in free-breathing mode, adopting a breath-hold technique will improve positioning and reduce dosimetric uncertainty.
In the prostate cohort the failures were due to bladder and rectal filling and in the H&N cancer group the alerts were as a result of weight loss and choice of the reference point used for analysis.
In the future the availability of IVD data, such as the data presented here, could be a powerful indicator of suboptimal treatments if correlated with long-term patient follow-up or outcome data. It could also be used, if processed immediately, to identify the correctness of individual multileaf collimator (MLC) fields 32 and to identify significant anatomical changes such as those seen in H&N cancer patients experiencing weight loss during treatment. 33 After the DC software obtains the in-air fluence in RMU it is possible to independently calculate the dose delivered to a given patient using the original planning CT scan. Currently the DC software uses a PBC algorithm to calculate this dose while the Eclipse treatment planning system used the Analytical Anisotropic Algorithm (AAA). 34 The AAA algorithm has been shown to result in a lower mean dose than the PBC and in general a reduction in dose to the planning target volume (PTV), which may in part account for the differences between the calculated and measured doses. 35 Other factors that contribute to the difference in dose observed in Fig. 2 include the EPID detector offaxis energy response and the fitting parameters for all field sizes and depths acquired by DC. To account for a portion of these differences a collapsed cone algorithm is currently under development by Math Resolutions, which will improve the accuracy of the dose calculation in DC and ultimately reduce the variability in the results. 36 The percentage difference between the measured and calculated Sc was found to be within ±1.0% for field sizes between 5 × 5 cm 
| CONCLUSIONS
The ability to perform patient-specific QA is now an accepted requirement in modern radiotherapy. This paper presents preliminary data, with a focus on safety, showing that EPID-based IVD with DC has significant potential for this. From knowledge of the expected difference between the in vivo dose and the planned dose, collected on a large number of cases, it may be possible to set site-specific alert criteria for a given treatment site. Furthermore, this approach has the potential to identify suboptimal treatments much earlier than is currently possible. 
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